title: Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
abstract: 1. Of 22 parkinsonians with fluctuations under long-dating dopatherapy in whom standard Madopar was substituted by the HBS form, 16 who performed the trial longer than 1 year were particularly studied to evaluate some parameters of this long-term follow-up (30-36 months). 2. The outstanding beneficial effects were an enhancement of the antiparkinsonian response, improvement or disappearance of motor oscillations, longer "on" periods, less severe "off" periods, and a more sustained nocturnal antiparkinsonian effect with a reduction of dystonias and pain at night and decreased or absent early morning parkinsonism. 3. The decrease or disappearance of dystonia was observed since the early stages of the trial and can be explained by the more sustained dopaminergic effect. 4. Surprisingly, dyskinesias also decreased in spite of the higher dopaminergic effect. The avoidance of sharp and repeated plasmatic peaks and the lower levels of L-dopa under HBS could explain this phenomenon. 5. The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning. 6. The dosage increase went up by 80% to 100% in relation to standard Madopar during the long-term treatment. 7. As Madopar HBS is a sustained release preparation, we had to increase the initially reduced the number of intakes, again in order to obtain better results. In the most severe cases with poor or absent response, benefits were achieved only when administering the HBS intake every hour.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Instituto de Neurologia, Universidad de la República, Montevideo, Uruguay.
authors.forename: C
authors.initials: C
authors.lastname: Chouza
authors.forename: R
authors.initials: R
authors.lastname: Aljanati
authors.forename: J L
authors.initials: JL
authors.lastname: Caamaño
authors.forename: O
authors.initials: O
authors.lastname: De Medina
authors.forename: A
authors.initials: A
authors.lastname: Scaramelli
authors.forename: R
authors.initials: R
authors.lastname: Buzó
authors.forename: V
authors.initials: V
authors.lastname: Plachín
authors.forename: A
authors.initials: A
authors.lastname: Fernandez
authors.forename: S
authors.initials: S
authors.lastname: Romero
mesh_terms: D000368:Aged; D001545:Benserazide / Q000008:administration & dosage*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008134:Long-Term Care; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide; D002262:Carboxy-Lyases